Navigation Links
Scientists find bone-marrow environment that helps produce infection-fighting T and B cells

DALLAS Feb. 24, 2013 The Children's Medical Center Research Institute at UT Southwestern has deepened the understanding of the environment within bone marrow that nurtures stem cells, this time identifying the biological setting for specialized blood-forming cells that produce the infection-fighting white blood cells known as T cells and B cells.

The research found that cells called early lymphoid progenitors, which are responsible for producing T cells and B cells, thrive in an environment known as an osteoblastic niche. The investigation, published online today in Nature and led by Dr. Sean Morrison, also establishes a promising approach for scientists to map the entire blood-forming system.

Scientists already know how to manufacture large quantities of stem cells that give rise to the nervous system, skin, and other tissues. But they have been unable to make blood-forming stem cells in a laboratory, in part because of a lack of understanding about the niche in which blood-forming stem cells and other progenitor cells reside in the body.

"We believe this research moves us one step closer toward the development of cell therapies in the blood-forming system that don't exist today," said Dr. Morrison, Director of the Institute and Professor of Pediatrics at UT Southwestern Medical Center. "In understanding the environments for blood-forming stem cells and those of different kinds of progenitor cells, we can work toward reproducing those environments in the lab and growing cells that can be transplanted to treat a host of medical conditions."

These findings eventually may help increase the safety and effectiveness of bone-marrow transplants, such as those needed after healthy marrow is destroyed by radiation or chemotherapy treatments for childhood leukemia, Dr. Morrison said. The findings also may have implications for treating illnesses associated with loss of infection-fighting cells, such as HIV and severe combined immunodeficiency disease, better known as bubble boy disease.

The Nature study augments earlier work by Dr. Morrison and his team that showed endothelial cells and perivascular cells lining the blood vessels in the bone marrow create the environment that maintains haematopoietic stem cells, which produce billions of new blood cells every day. The latest study shows that bone-forming cells create the environment that maintains early lymphoid progenitors.

"Our research documents that there are different niches, or microenvironments, for blood-forming stem cells and restricted progenitors in the bone marrow," Dr. Morrison said. "One way that bone marrow makes different kinds of blood-forming cells is by compartmentalizing them into different neighborhoods within the marrow."

The researchers identified niches for stem cells and early lymphoid progenitors by determining which cells are the sources of a growth factor (CXCL12) necessary for the proliferation of those two populations of blood-forming cells. By taking the same approach for other growth factors in the bone marrow, researchers should be able to map the niches for every kind of blood-forming progenitor cell in the bone marrow, Dr. Morrison said.

The UTSW paper's first author is Dr. Lei Ding, a former postdoctoral research fellow at the Children's Research Institute and the Howard Hughes Medical Institute (HHMI) at UT Southwestern. Dr. Ding is now an assistant professor at Columbia University.


Contact: Jeff Carlton
UT Southwestern Medical Center

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
Related Image:
Scientists find bone-marrow environment that helps produce infection-fighting T and B cells
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: